Adaptive Biotechnologies: First Primary Endpoint Milestone + Raised Guidance Signal Inflection

MRD momentum drives 53% revenue growth and a step-change in clinical adoption

ADPT · Earnings Call · 2026-05-05

The inflection in MRD is real

At first glance, Adaptive Biotechnologies' stock looks like it's been through a roller coaster: after a brutal drawdown from 2021, the shares have surged 103% over the last 90 trading days. That move is now backed by a quarter that would support a re-rating. In its Q1 2026 report, the company's primary endpoint story finally has a tangible proof point, and the year is being guided upward.

We also recognized our first primary endpoint milestone this quarter, a meaningful proof point for MRD's expanding role in drug development.
Chad M. Robins, CEO · 2026-05-05

The milestone, tied to the CEPHIUS trial in multiple myeloma, is a watershed for the company's biopharma franchise. It validates the clamor around MRD as an endpoint, and it comes as the backlog has reached roughly $254 million, up 24% year over year. As Susan Bobulsky, Chief Commercial Officer, noted, "we are seeing increasing use of the assay in the pharma setting in terms of regulated studies... and we are extremely well positioned to capture these opportunities." This is not just a one-off; it is the beginning of a flywheel that connects pharma evidence with clinical adoption.

Volume growth and guidance raise

The clinical business is firing on all cylinders. clinical volume grew 41% year over year, and the company now expects at least 35% volume growth for 2026, up from 30% previously. The mix shift toward blood based testing continues to accelerate, reaching 49% of volume overall and 29% in multiple myeloma. The community channel is a big driver: "One year ago, if you had asked me this question, I would have said the conversations had shifted from 'What is MRD? Why should I care?' to 'How should I do this?'" Susan Bobulsky captured the maturation. The company is now embedding protocols in large community networks, and EMR integrations (including seven of the top ten academic accounts and 150 community sites) are lifting repeat utilization. Serial monitoring orders are pulling through at 72% of repeat due dates. The raised full-year MRD revenue guidance to $260-270 million (from $255-265 million) is a direct consequence. As CFO Kyle Piskel explained, "The momentum we are seeing in the pharma business is likely to be further supported by evolving regulatory trends... and we have a strong backlog going into the year." The company is also digesting the first major milestone payment of $9 million, with no additional milestone expected for the rest of the year—a signal that the core recurring business is carrying the load.

Margin expansion and the path to profitability

Beyond the top line, the economics are improving meaningfully. Sequencing gross margin expanded eight percentage points to 70% in the quarter, and the company sees a path to 75% as the "north star." This scale leverage, combined with disciplined spending, brought total company adjusted EBITDA to a $2.5 million loss, with the MRD segment generating $12.1 million of adjusted EBITDA. In contrast with a year ago, when Margins were far thinner, the operating model is clearly inflecting.

The broader market context

This quarter also resonates with a global theme: the regulatory tailwind for MRD as a trial endpoint. The FDA's new real-time data submission model, including the TRAVERSE trial in mantle cell lymphoma, is an early proof of concept. While the global keyword track for "primary endpoint" appears in other companies' trajectories, it's the company-specific combination of a first milestone, a raised guide, and gross margin expansion that makes this report stand out. The stock's 103% rally in three months is a forward-looking bet on exactly this momentum. Prior calls laid the groundwork: in 2025, management repeatedly discussed the potential for MRD as a primary endpoint but had no concrete payment. As Susan noted in a prior call, "We are seeing -- continuing to see an acceleration. And I think particularly in those large accounts, those growth rates are quite -- I'm quite pleased with them." Now, with the first milestone realized, the conversation shifts from "when" to "how much." As Chad Robins said on an earlier call, "there is a growing global support for MRD to use as an endpoint for the acceleration of therapy," and that support is now translating into revenue. The next question is whether the company can sustain this cadence and convert the backlog at a faster rate. With a cash balance of ~$222 million and a path to positive free cash flow in 2026, the risk-reward has improved. Investors who missed the rally may wait for a pullback, but the fundamental story is now backed by measurable traction.